Allogene Therapeutics (ALLO) announced that it has entered into a non-exclusive licensing agreement with privately-held Arbor Biotechnologies to utilize the latter’s proprietary CRISPR gene-editing technology. Allogene intends to utilize Arbor’s CRISPR technology with its own proprietary platform to develop next- generation allogeneic CAR T (AlloCAR T) therapies targeting autoimmune diseases (AID). However, neither of the companies disclosed any specific financial terms or considerations pertaining to the a ...